Key facts
- Aavantgarde’s last known valuation is $12.7M (Jun 2021).
- It has raised $211.4M; the latest was Early Stage VC ($141.0M) in Nov 2025.
- Notable investors include CDP Venture Capital (Rome), Sofinnova Partners, Forbion, NEVA SGR, Atlas Venture — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Aavantgarde
- ·The full record, as it builds
Funding rounds
No funding rounds for Aavantgarde are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aavantgarde
Developer of a gene therapy technology designed for inherited retinal disorders. The company builds on proprietary Adeno-Associated Viral (AAV) vector platforms to address the gene therapy cargo capacity limitations of AAV vectors and deliver large genes to ocular and non-ocular tissues, enabling patients to deliver large genes to tissues and cells in vivo.
- Sector
- Healthcare
- HQ
- Rome, Italy
- Founded
- 2021
- Employees
- 27
- Website
- aavantgarde.com/
- Ownership
- Privately Held (backing)
Aavantgarde doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aavantgarde shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aavantgarde in its N-PORT filings yet. We sweep new filings monthly.